Guggenheim raised the firm’s price target on GeneDx (WGS) to $170 from $115 and keeps a Buy rating on the shares following what the firm calls out as another quarter of whole exome and genome growth, strong average selling prices, and gross margin improvements. With “a large beat and even larger guidance raise,” the firm does not believe management intended to signal a move to negative EPS despite management’s comments on 2026 operating expenses, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- Genedx Holdings Corp. Maintains Stable Risk Profile in 2025 Reports
- GeneDx Reports Strong Q3 2025 Financial Growth
- GeneDx’s Earnings Call Highlights Robust Growth and Optimism
- GeneDx Holdings: Strong Q3 Performance and Strategic Expansion in Pediatric Market Drive Optimistic Outlook
- GeneDx files automatic mixed securities shelf